Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brazikumab Phase 2b in Crohn's Disease
NCT02574637Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of brazikumab in Crohn's disease (5 arms), sponsored by AstraZeneca. Primary endpoint: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Remission at Week 8. Started Jan 2016; status: terminated.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02574637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574637.